HLA-DRB1 polymorphism in recurrent pregnancy loss: New evidence for an association to HLA-DRB1*07.


Journal

Journal of reproductive immunology
ISSN: 1872-7603
Titre abrégé: J Reprod Immunol
Pays: Ireland
ID NLM: 8001906

Informations de publication

Date de publication:
06 2021
Historique:
received: 16 10 2020
revised: 15 01 2021
accepted: 03 03 2021
pubmed: 17 3 2021
medline: 15 12 2021
entrez: 16 3 2021
Statut: ppublish

Résumé

Many cases of recurrent pregnancy loss (RPL) defined as ≥3 consecutive pregnancy losses are suggested to be caused by an aberrant maternal immune response against the fetus or trophoblast. Human leukocyte antigen (HLA)-DRB1 and -DQB1 polymorphisms are associated with most autoimmune disorders and studies of HLA-DBB1 polymorphism in RPL patients are thus relevant. In previous studies, the HLA-DRB1*03 allele was found with increased prevalence in RPL patients. We wanted to clarify whether HLA-DRB1 alleles indeed were associated with RPL among women of Caucasian descent. A total of 1078 women with unexplained RPL and 2066 bone marrow donors were HLA-DRB1-typed and subsets were also HLA-DQB1 typed. All patients were initially HLA-DRB1-typed by DNA-based low-resolution techniques and subsets of patients and all controls were typed by high-resolution techniques. Among patients, the HLA-DRB1*07 allele frequency was significantly increased compared with controls; OR 1.29 (95 % CI 1.09-1.52), p < 0.0025; after correction for multiple comparisons pc = 0.031. The HLA-DRB1*07/*07 genotype was highly increased in patients with RPL compared with controls: OR 2.27 (1.31-3.93), p = 0.0027. The frequency of the HLA-DRB1*07 phenotype in RPL patients had increased significantly (p = 0.002) in three studies from our group published 1994-2021. The allele frequency of HLA-DRB1*03 was not increased in RPL patients compared with controls; OR 0.96 (0.83-1.12). In conclusion, the previous association between HLA-DRB1*03 and RPL could not be confirmed in our study whereas an association to HLA-DRB1*07 was detected for the first time. Since the latter association is a new finding, it should be confirmed in future studies.

Identifiants

pubmed: 33725525
pii: S0165-0378(21)00038-3
doi: 10.1016/j.jri.2021.103308
pii:
doi:

Substances chimiques

HLA-DRB1 Chains 0
HLA-DRB1*07 antigen 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

103308

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

Auteurs

C K Thomsen (CK)

Centre for Recurrent Pregnancy Loss of Western Denmark, Department of Obstetrics and Gynaecology, Aalborg University Hospital, Aalborg, Denmark.

R Steffensen (R)

Department of Clinical Immunology, Aalborg University Hospital, Aalborg, Denmark.

H S Nielsen (HS)

Recurrent Pregnancy Loss Unit Capital Region, Copenhagen University Hospital, Rigshospitalet and Hvidovre Hospital, Copenhagen, Denmark; Department of Obstetrics and Gynaecology, Hvidovre Hospital, Copenhagen University Hospital, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Denmark.

A M Kolte (AM)

Recurrent Pregnancy Loss Unit Capital Region, Copenhagen University Hospital, Rigshospitalet and Hvidovre Hospital, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Denmark.

M C Krog (MC)

Recurrent Pregnancy Loss Unit Capital Region, Copenhagen University Hospital, Rigshospitalet and Hvidovre Hospital, Copenhagen, Denmark; Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Denmark.

P Egerup (P)

Recurrent Pregnancy Loss Unit Capital Region, Copenhagen University Hospital, Rigshospitalet and Hvidovre Hospital, Copenhagen, Denmark; Department of Obstetrics and Gynaecology, Hvidovre Hospital, Copenhagen University Hospital, Copenhagen, Denmark.

E C Larsen (EC)

Recurrent Pregnancy Loss Unit Capital Region, Copenhagen University Hospital, Rigshospitalet and Hvidovre Hospital, Copenhagen, Denmark.

T V Hviid (TV)

Department of Clinical Biochemistry, Centre for Immune Regulation and Reproductive Immunology (CIRRI), the ReproHealth Research Consortium ZUH, Zealand University Hospital and Department of Clinical Medicine, University of Copenhagen, Denmark.

O B Christiansen (OB)

Centre for Recurrent Pregnancy Loss of Western Denmark, Department of Obstetrics and Gynaecology, Aalborg University Hospital, Aalborg, Denmark; Recurrent Pregnancy Loss Unit Capital Region, Copenhagen University Hospital, Rigshospitalet and Hvidovre Hospital, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health Sciences, Aalborg University, Denmark. Electronic address: olbc@rn.dk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH